Allergic reactions can happen.
Allergic reactions have been noted in patients treated with VYONDYS 53, including:
Seek immediate medical care if signs and symptoms of allergic reactions happen.
Kidney Monitoring for Safety
Damage to the kidneys was seen in animals who received golodirsen. Although damage to the kidneys was not seen in clinical studies with VYONDYS 53, the clinical experience with VYONDYS 53 is limited. Fatal kidney damage has occurred with other drugs that work in a similar way. Your doctor may recommend urine collection and blood testing before starting treatment followed by urine testing every month and a blood test every 3 months to monitor your kidneys.
Common side effects.
Side effects observed in at least 20% of treated patients and greater than placebo were (VYONDYS 53, Placebo)
Other Side Effects
The following side effects occurred in greater than 5% of patients who received VYONDYS 53 and more often than in patients who received an inactive IV infusion:
A phone call away
As with any medication, please talk to your doctor if you experience any side effects from VYONDYS 53. We encourage you to report negative side effects of all prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Sarepta Therapeutics at 1-888-SAREPTA (1-888-727-3782).
Please see the full Prescribing Information for VYONDYS 53 (golodirsen).
Weekly infusions of VYONDYS 53 helped the body make a shorter form of the dystrophin protein in some boys. View the results from clinical studies.
VYONDYS 53 is used to treat patients with Duchenne muscular dystrophy (DMD) who have a confirmed mutation in the dystrophin gene that can be treated by skipping exon 53.
This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53. Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials.